摘要
目的探讨固本咳喘胶囊联合噻托溴铵吸入粉雾剂治疗慢性阻塞性肺疾病稳定期的临床疗效。方法选取2018年8月—2020年7月在河南科技大学第二附属医院就诊的90例慢性阻塞性肺疾病患者作为研究对象,按照随机数字表法将90例患者分为对照组和治疗组,每组各45例。对照组雾化吸入噻托溴铵吸入粉雾剂,18μg/次,1次/d。治疗组在对照组基础上口服固本咳喘胶囊,4粒/次,3次/d。两组患者连续治疗3个月。观察两组的临床疗效,并比较两组的肺功能指标、血清炎症因子水平。结果治疗后,治疗组的总有效率为95.56%,对照组的总有效率为82.22%,组间比较有明显差异(P<0.05)。治疗后,两组的第1秒钟用力呼吸容积(FEV1)/用力肺活量(FVC)、最大呼气流量(PEF)、第一秒用力呼气容积占预计值百分比(FEV1 pre)显著升高(P<0.05);且治疗组的肺功能指标比对照组高,差异有统计学意义(P<0.05)。治疗后,两组的白细胞介素-17(IL-17)、肿瘤坏死因子-α(TNF-α)、和肽素(copeptin)水平显著降低(P<0.05);且治疗后治疗组的IL-17、TNF-α、copeptin水平比对照组低,差异有统计学意义(P<0.05)。结论固本咳喘胶囊联合噻托溴铵吸入粉雾剂可提高慢性阻塞性肺疾病稳定期的疗效,改善肺功能,有助于降低炎症因子的水平,且安全性良好。
Objective To investigate the clinical efficacy of Guben Kechuan Capsules combined with Tiotropium Bromide Powder for inhalation in treatment of stable chronic obstructive pulmonary disease.Methods Patients(90 cases)with stable chronic obstructive pulmonary disease in the Second Affiliated Hospital of Henan University of Science and Technology from August 2018 to July 2020 were randomly divided into control and treatment groups,and each group had 45 cases.Patients in the control group were atomization inhalation of Tiotropium Bromide Powder for inhalation,18μg/time,once daily.Patients in the treatment group were po administered with Guben Kechuan Capsules on the basis of the control group,4 grains/time,three times daily.Patients in two groups were treated for 3 months.After treatment,the clinical efficacies were evaluated,and the lung function indexes and serum inflammatory factors of two groups were compared.Results After treatment,the total effective rate of the treatment group was 95.56%,and that of the control group was 82.22%,and there was a significant difference between the two groups(P<0.05).After treatment,the FEV1/FVC,PEF,FEV1 pre of two groups were significantly increased(P<0.05).And after treatment,the FEV1/FVC,PEF,and FEV1 pre of the treatment group were higher than those of the control group,and the difference was statistically significant(P<0.05).After treatment,the levels of IL-17,TNF-α,and copeptin in two groups were significantly decreased(P<0.05).After treatment,the levels of IL-17,TNF-α,and copeptin in the treatment group were lower than those in the control group,and the difference was statistically significant(P<0.05).Conclusion Guben Kechuan Capsules combined with Tiotropium Bromide Powder for inhalation can improve the curative effect of stable chronic obstructive pulmonary disease,improve lung function,help to reduce the level of inflammatory factors,with good safety.
作者
张冠磊
李向前
兰文静
罗东娟
ZHANG Guan-lei;LI Xiang-qian;LAN Wen-jing;LUO Dong-juan(Department of Respiratory and Critical Care Medicine,the Second Affiliated Hospital of Henan University of Science and Technology,Luoyang 471000,China)
出处
《现代药物与临床》
CAS
2021年第3期490-493,共4页
Drugs & Clinic
基金
河南省医学科技攻关计划联合共建项目(LHGJ20191299)。
关键词
固本咳喘胶囊
噻托溴铵吸入粉雾剂
慢性阻塞性肺疾病稳定期
肺功能
炎症因子
Guben Kechuan Capsules
Tiotropium Bromide Powder for inhalation
stable chronic obstructive pulmonary disease
inflammatory factor
lung function
